⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Zylö Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Zylö Therapeutics
↗Greenville, South Carolina, USA
Zylö Therapeutics is a biotech company specializing in innovative topical drug delivery technology. Founded in 2017, the company has developed the patented Z-pod® (Powered by Z-pods®) platform—a disruptive sustained-release delivery system using engineered silica-derived nanoparticles licensed from Albert Einstein College of Medicine. The Z-pod technology enables extended duration of effect (24+ hours versus 30-60 minutes without the technology), improved bioavailability, enhanced targeting of skin pores and hair follicles, and enhanced product performance. The company addresses critical challenges in solubility, bioavailability, and targeted delivery for therapeutic and cosmetic applications. Zylö operates in three verticals: cosmetic/OTC (through partnerships with YuvaBio and CielementsMD), pharmaceutical (through spinout Atticus Pharma), and emerging applications including animal health and agricultural chemicals.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Drug Delivery Technology / Topical Therapeutics
SIZE & FINANCIALS
Employees:11-50
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$19.5M
Investors:VentureSouth (led Series A, >$1M investment), New York Angels, Ariel Southeast Angel Partners (ASAP, Savannah), Boston Harbor Angels, Chemical Angel Network, James Cordes (Series B board member), Endless Frontier Labs, National Institutes of Arthritis and Musculoskeletal Diseases, National Institute of Allergy and Infectious Diseases, Arcview Ventures, NIH Seed, SC Launch Inc., South Carolina Research Authority (SCRA)
PIPELINE
Stage:Commercial (cosmetic/OTC), Clinical (pharmaceutical)
Lead Drug Stage:Commercial - Y100-loaded Z-pods in cosmetic/OTC; Clinical Phase I/II - Y200-loaded Z-pods for alopecia and wound healing via Atticus Pharma
Modalities:Topical delivery, Silica nanoparticles (Z-pods), Sustained-release formulations
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Atticus Pharma Inc. (spinout created April 2024, focuses on pharmaceutical vertical)
Key Partnerships:Albert Einstein College of Medicine (technology license), YuvaBio (Y100 anti-aging ingredient partnership), BosleyMD (Revive+ Hair Densifying Foam - commercial in CVS, Walmart, Ulta Beauty, Rite-Aid, Kroger, Meijer), CielementsMD/MINO Labs (Daily DNA Defense™ sunscreen product), Atticus Pharma (spun-out subsidiary for pharma vertical), Silo Pharma (joint venture for ketamine transdermal delivery), XXIV Skincare (twentyfour product line launch 2025), Yuva Biosciences (exclusive rights to Y200™ through Atticus)
COMPETITION
Position:Emerging - Innovative topical delivery technology with commercial traction in cosmetics/OTC; early pharmaceutical development stage
Competitors:3M Drug Delivery Systems, Noven Pharmaceuticals, Hisamitsu Pharmaceutical (transdermal leaders), Other topical delivery platforms, Traditional formulations without sustained release
LEADERSHIP
Key Executives:
Scott R. Pancoast - CEO and Founder
Charles E Hinkle - Chief Financial Officer
John Lind - Vice President, Operations & Planning
Jay Blankenship - Vice President, Business Development
Michael R. - Vice President, Strategy
Michael Burns - Vice President
Andrew Draganski - Director, Product Development
Scientific Founders:Albert Einstein College of Medicine (Z-pod technology inventors/licensors)
Board Members:Scott R. Pancoast (CEO, Founder, Chairman), James Cordes (Series B lead, joined board 2022)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Zylö Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.